Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020

被引：3

作者：

Huntington, Scott F. ^{[1
]}

Ingham, Michael P. ^{[2
]}

Okonkwo, Linda ^{[3
]}

Singh, Ajaybir ^{[4
]}

Wang, Ruibin ^{[2
,5
]}

Ammann, Eric M. ^{[3
]}

机构：

[1] Yale Sch Med, New Haven, CT USA

[2] Janssen Sci Affairs, Titusville, NJ USA

[3] Janssen Res & Dev, 920 US Highway 202 S, Raritan, NJ 08869 USA

[4] Mu Sigma, Bangalore, Karnataka, India

[5] Harvard TH Chan Sch Publ Hlth, Boston, MA USA

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 05期

关键词：

Acute myeloid leukemia; older adults; treatment patterns; economic burden of disease; overall survival; healthcare resource utilization; RESOURCE UTILIZATION; CARE; CHEMOTHERAPY; AZACITIDINE; COSTS; VENETOCLAX;

D O I：

10.1080/10428194.2021.2012666

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The present study assessed changes in patient management, economic burden, and overall survival (OS) in a contemporary cohort of 2775 US Medicare Advantage beneficiaries aged >= 66 years newly diagnosed with acute myeloid leukemia (AML) between 01 January 2015 and 30 June 2020. Use of venetoclax-based therapy increased and replaced hypomethylating agent (HMA) monotherapy as the most common first-line treatment choice in 2019-2020. In newly diagnosed AML patients aged >= 75 and 66-74 years, mean per-patient 1-year healthcare expenditures were $81,818 and $156,033 (2020 USD) and median OS was 2.3 and 8.5 months, respectively. In addition, 40% of Medicare Advantage patients with newly diagnosed AML continue to receive supportive care alone. These findings indicate that at the population level clinical outcomes remain poor for older adults with AML, pointing to a continuing unmet medical need.

引用

页码：1180 / 1190

页数：11

共 26 条

[1] Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States [J].

Bell, Jill A. ;

Galaznik, Aaron ;

Farrelly, Eileen ;

Blazer, Marlo ;

Murty, Sharanya ;

Ogbonnaya, Augustina ;

Eaddy, Michael ;

Fram, Robert J. ;

Faller, Douglas, V ;

Kota, Vamsi .

LEUKEMIA RESEARCH, 2018, 71 :27-33

[2] Mortality Differences Between Traditional Medicare and Medicare Advantage: A Risk-Adjusted Assessment Using Claims Data [J].

Beveridge, Roy A. ;

Mendes, Sean M. ;

Caplan, Arial ;

Rogstad, Teresa L. ;

Olson, Vanessa ;

Williams, Meredith C. ;

McRae, Jacquelyn M. ;

Vargas, Stefan .

INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING, 2017, 54

[3]

Clinformatics®, 2019, DAT MART US MAN VERS

[4] Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia [J].

DiNardo, C. D. ;

Jonas, B. A. ;

Pullarkat, V. ;

Thirman, M. J. ;

Garcia, J. S. ;

Wei, A. H. ;

Konopleva, M. ;

Doehner, H. ;

Letai, A. ;

Fenaux, P. ;

Koller, E. ;

Havelange, V. ;

Leber, B. ;

Esteve, J. ;

Wang, J. ;

Pejsa, V. ;

Hajek, R. ;

Porkka, K. ;

Illes, A. ;

Lavie, D. ;

Lemoli, R. M. ;

Yamamoto, K. ;

Yoon, S. -S. ;

Jang, J. -H. ;

Yeh, S. -P. ;

Turgut, M. ;

Hong, W. -J. ;

Zhou, Y. ;

Potluri, J. ;

Pratz, K. W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) :617-629

[5] International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts [J].

Dombret, Herve ;

Seymour, John F. ;

Butrym, Aleksandra ;

Wierzbowska, Agnieszka ;

Selleslag, Dominik ;

Jang, Jun Ho ;

Kumar, Rajat ;

Cavenagh, James ;

Schuh, Andre C. ;

Candoni, Anna ;

Recher, Christian ;

Sandhu, Irwindeep ;

Bernal del Castillo, Teresa ;

Al-Ali, Haifa Kathrin ;

Martinelli, Giovanni ;

Falantes, Jose ;

Noppeney, Richard ;

Stone, Richard M. ;

Minden, Mark D. ;

McIntyre, Heidi ;

Songer, Steve ;

Lucy, Lela M. ;

Beach, C. L. ;

Doehner, Hartmut .

BLOOD, 2015, 126 (03) :291-299

[6] Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making [J].

Ferrara, F. ;

Barosi, G. ;

Venditti, A. ;

Angelucci, E. ;

Gobbi, M. ;

Pane, F. ;

Tosi, P. ;

Zinzani, P. ;

Tura, S. .

LEUKEMIA, 2013, 27 (05) :997-999

[7]

Fitch KR, 2019, The Cost Burden of Blood Cancer Care in Medicare: A Longitudinal Analysis of Medicare Advantage and Fee for Service Patients Diagnosed with Blood Cancer Milliman Research Report

[8] Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia [J].